Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Rigel Pharmaceuticals, Inc. (RIGL) - Financial and Strategic SWOT Analysis Review

VIEWS: 19 PAGES: 37

Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company with focus on the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases and muscle disorder. Rigel develops its products based on signaling pathways and related targets that are critical for disease mechanisms. The company's products under pipeline are R343 to treat asthma; R333, a JAK/SYK inhibitor for the treatment of discoid lupus; R548 JAK3 inhibitor for the treatment of transplant rejection; AMPK activator for muscle endurance and fostamitinib for the treatment of rheumatoid arthritis; R348 for dry eye treatment and GDF8 inhibitor for muscle atrophy. Rigel established strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Rigel is headquartered in South San Francisco, California, the US. The company strategically intends to develop partnerships with other pharmaceutical companies for the developments of its products and expand its product portfolio.

More Info
									              Rigel Pharmaceuticals, Inc. (RIGL) - Financial and Strategic SWOT
                                      Analysis Review
        Reference Code: GDPH32587FSA                                                                                          Publication Date: AUG 2012

          1180 Veterans Blvd                                 Phone              +1 650 6241100                  Revenue          4.8 (million USD)
          South San Francisco, CA                            Fax                +1 650 6241101                  Net Profit       -85.97 (million USD)
          94080                                              Website            www.rigel.com                   Employees        153
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           RIGL [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company with focus on the discovery and development of
       novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases and muscle disorder. Rigel develops its
       products based on signaling pathways and related targets that are critical for disease mechanisms.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Rigel Pharmaceuticals, Inc., SWOT Analysis
         James M. Gower                      Chairman                                 Strengths                              Weaknesses
         Donald G. Payan                     Director
                                                                                      Strong Patent Portfolio                Legal Proceedings
         Bradford S. Goodwin                 Director
                                                                                      Sturdy R&D Activities                  History of Losses
         Gary A. Lyons                       Director
         Walter H. Moos, Ph.D.               Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Strong Product Pipeline                Uncertain R&D Outcomes
       Share Data
                                                                                      Emerging Markets                       Stringent Government
         Rigel Pharmaceuticals, Inc.
                                                                                                                             Regulations
        Share Price (USD) as on 03-Aug-                                10.61
        2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -1.36        GlobalData
        Market Cap (million USD)                                         627
        Enterprise Value (million USD)                                   605
        Shares Outstanding (million)                                       71
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 01, 2012         Rigel Pharma Reports Q1 2012 Results
                                                                                      Mar 06, 2012         Rigel Pharma Reports Q4 2011 Results
                                                                                      Nov 01, 2011         Rigel Pharma Reports Revenue Of $4.4m In
                                                                                                           Q3 2011
                                                                                      Aug 02, 2011         Rigel Reports Contract Revenues Of $0.4m
                                                                                                           For Q2 2011
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Rigel Pharmaceuticals, Inc. (RIGL) - Financial and Strategic SWOT                                                              Reference Code: GDPH32587FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Rigel Pharmaceuticals, Inc. - Key Facts ............................................................................................................................................. 5
       Rigel Pharmaceuticals, Inc. - Key Employees .................................................................................................................................... 6
       Rigel Pharmaceuticals, Inc. - Key Employee Biographies .................................................................................................................. 7
       Rigel Pharmaceuticals, Inc. - Major Products and Services ............................................................................................................... 8
       Rigel Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................... 9
          Rigel Pharmaceuticals, Inc., Pipeline Products by Therapy Area ................................................................................................... 9
          Rigel Pharmaceuticals, Inc., Pipeline Products by Development Phase ....................................................................................... 10
       Rigel Pharmaceuticals, Inc. - History ................................................................................................................................................ 12
       Rigel Pharmaceuticals, Inc. - Company Statement .......................................................................................................................... 13
       Rigel Pharmaceuticals, Inc. - Locations And Subsidiaries ................................................................................................................ 15
          Head Office ................................................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Rigel Pharmaceuticals, Inc. - Business Description ......................................................................................................................... 16
       Rigel Pharmaceuticals, Inc. - Corporate Strategy............................................................................................................................. 17
       Rigel Pharmaceuticals, Inc. - SWOT Analysis .................................................................................................................................. 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          Rigel Pharmaceuticals, Inc. - Strengths ........................................................................................................................................ 18
             Strength - Strong Patent Portfolio ............................................................................................................................................. 18
             Strength - Sturdy R&D Activities ............................................................................................................................................... 18
             Strength - Strategic Alliances .................................................................................................................................................... 18
          Rigel Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................... 18
             Weakness - Legal Proceedings ................................................................................................................................................. 18
             Weakness - History of Losses ................................................................................................................................................... 19
             Weakness - Reliance on Third Parties ...................................................................................................................................... 19
          Rigel Pharmaceuticals, Inc. - Opportunities .................................................................................................................................. 19
             Opportunity - Strong Product Pipeline ....................................................................................................................................... 19
             Opportunity - Emerging Markets ............................................................................................................................................... 19
             Opportunity - Changing Demographics ..................................................................................................................................... 19
          Rigel Pharmaceuticals, Inc. - Threats ........................................................................................................................................... 20
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
             Threat - Stringent Government Regulations .............................................................................................................................. 20
             Threat - Competitive Pressures ................................................................................................................................................. 20
       Rigel Pharmaceuticals, Inc. - Key Competitors ................................................................................................................................ 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 24
       Financial Performance...................................................................................................................................................................... 24
       Financial Ratios - Interim Ratios....................................................................................................................................................... 25
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 26
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 27


Rigel Pharmaceuticals, Inc. (RIGL) - Financial and Strategic SWOT                                                                                              Reference Code: GDPH32587FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012................................................. 27
          Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................................ 28
       Rigel Pharmaceuticals, Inc., Recent Deals Summary ...................................................................................................................... 29
       Section 5 – Company’s Recent Developments ................................................................................................................................ 30
          Rigel Pharmaceuticals, Inc., Recent Developments .............................................
								
To top